Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : , Nitto, and M. Heart Partnering for ECG testing service

09/02/2021 | 02:12am EDT

-Total Solution for Early Detection of Atrial Fibrillation Using
Disposable Holter ECG device and AI-Based Analysis Service-

TOKYO, OSAKA, and IWATE, September 2nd, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas' ), Nitto Denko Corporation (TSE: 6988, President; Hideo Takasaki, 'Nitto'), and M. Heart Co., Ltd. (President and CEO: Yoshimi Mizunuma, 'M. Heart') today announced that the three companies concluded a memorandum of understanding on September 1st concerning an ECG testing service.

Based on this memorandum of understanding, Astellas, Nitto, and M. Heart will continue to look into Nitto developing and manufacturing the 'EG Holter' a novel disposable holter ECG device, and Astellas exclusively selling it in Japan. M. Heart will play the role of marketing authorization holder of the EG Holter following from its background of providing development support and regulatory affairs consultations and be responsible for providing the service that will analyze the data obtained from the EG Holter through 'MYHOLTER II,' a software for the Holter analyzer ('The ECG testing service'). In the future, Astellas will aim to provide EG Holter nationwide following pilot-sales.

The EG Holter is disposable and hygienic. It is 6 millimeters thick,11 grams in weight, has no cords, and is waterproof (IPX4). Patients thus can wear it more comfortably. M. Heart obtained certification for the EG Holter as a medical device (Class II) in August 2021.

Disposable Holter ECG device 'EG Holter'

Astellas and M. Heart have developed 'MYHOLTER II*1 jointly and built it into M. Heart's cloud-type Holter ECG analysis service*2 in July for provision to healthcare professionals. MYHOLTER II is a system that analyzes Holter ECG data efficiently with high accuracy using unique artificial intelligence (AI). With the ECG testing service, after measurement, patients return it to the reception center by postal mail, eliminating the need to return the equipment back to a medical institution. Medical institutions can also see results online via MYHOLTER II, resulting in the reducing of the burden on both patients and medical institutions.

The process for analysis by EG Holter

Medical costs for heart diseases and other cardiovascular diseases in Japan exceed 6 trillion yen per year-the highest of any disease category1. Of particular concern is cardiogenic cerebral embolism, which occurs when a thrombus that formed in the heart blocks an artery in the brain or neck. This has a high mortality rate (20%) and often results in severe sequelae, such as a bedridden state (40%)1. Atrial fibrillation is said to be the cause of cardiogenic cerebral embolism in 3 out of 4 cases2. Early detection of atrial fibrillation is an important social issue.

By providing a total solution that involves the combining of convenient ECG testing using the EG Holter and the effective and highly accurate data analysis using MYHOLTER II, Astellas, Nitto, and M. Heart are hoping that by promoting early detection and appropriate treatment of atrial fibrillation, a condition estimated to affect approximately 700,000 patients in Japan2 they can contribute to the prolongation of healthy life expectancy.

Click below for a copy of the full press release


Astellas Pharma Inc. published this content on 02 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 September 2021 06:11:03 UTC.

© Publicnow 2021
10/19ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”..
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
More news
Sales 2022 1 327 B 11 688 M 11 688 M
Net income 2022 196 B 1 723 M 1 723 M
Net cash 2022 584 B 5 142 M 5 142 M
P/E ratio 2022 18,4x
Yield 2022 2,55%
Capitalization 3 627 B 31 899 M 31 957 M
EV / Sales 2022 2,29x
EV / Sales 2023 2,05x
Nbr of Employees 15 455
Free-Float 98,9%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 957,50 JPY
Average target price 2 486,15 JPY
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985